Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens.

Robak, Pawel; Szemraj, Janusz; Mikulski, Damian; Drozdz, Izabela; Juszczak, Karolina; Jarych, Dariusz; Misiewicz, Malgorzata; Koscielny, Kacper; Fendler, Wojciech; Robak, Tadeusz

Robak, Pawel; Szemraj, Janusz; Mikulski, Damian; Drozdz, Izabela; Juszczak, Karolina; Jarych, Dariusz; Misiewicz, Malgorzata; Koscielny, Kacper; Fendler, Wojciech; Robak, Tadeusz.

Afiliación

Robak P; Department of Experimental Hematology, Medical University of Lodz, 93-510 Lodz, Poland.
Szemraj J; Department of Medical Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland.
Mikulski D; Department of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland.
Drozdz I; Department of Clinical Genetics, Medical University of Lodz, 92-213 Lodz, Poland.
Juszczak K; Department of Medical Biochemistry, Medical University of Lodz, 92-215 Lodz, Poland.
Jarych D; Laboratory of Personalized Medicine, Bionanopark, 93-465 Lodz, Poland.
Misiewicz M; Laboratory of Virology, Institute of Medical Biology, Polish Academy of Sciences, 93-232 Lodz, Poland.
Koscielny K; Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland.
Fendler W; Department of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland.
Robak T; Department of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland.

J Clin Med ; 10(21)2021 Oct 28.

Article en En | MEDLINE | ID: mdl-34768548

Palabras clave

MAFb; OS; PFS; POMP; bortezomib; cMAF; multiple myeloma; prognosis; survival

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: J Clin Med Año: 2021 Tipo del documento: Article País de afiliación: Polonia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google